Q1 2026 Earnings (April 14, 2026): Critical Thresholds

The Q1 report is the first earnings cycle post-headquarters opening (February 25, 2026) and will set the narrative for 2026. Key metrics to watch:

• EPS Threshold: $4.50+ validates underlying earnings power; below $4.20 signals NII compression accelerating faster than fee income recovery
• NII Language: 'Stable' or 'modestly lower' is bullish; 'down mid-single digits' is bearish—every 100bps of NII guidance change equals $1.80/share annual EPS sensitivity
• Expense Commentary: Look for 'positive operating leverage' from headquarters synergies; failure to quantify savings suggests execution risk
• Credit Provision: Q1 build toward $1.5-2.0B quarterly run-rate would signal normalization; sustained $1.0-1.2B is bullish
• IB/Markets Revenue: 10%+ sequential growth from Q4 2025's depressed base needed to support fee income recovery narrative

Q2 2026: CCAR and SCB Resolution

The June CCAR submission and July stress test results are the definitive capital events. Thresholds: SCB at or below 3.0% supports $20B+ buyback; above 3.5% forces capital return framework revision. Watch for Fed 'qualitative objection' language—any mention of 'governance' or 'controls' would trigger immediate 5-10% derating regardless of quantitative results.

Cross-Quarter Themes

Tokenized money market fund traction: $5B+ AUM by Q2 would signal institutional adoption acceleration; minimal disclosure suggests 2027+ relevance. M&A commentary: Any 'active pipeline' language from Dimon would support IB recovery thesis; silence confirms fee income dependence on market conditions.

Catalyst 1: SCB Finalization / Capital Return Clarity

Probability of occurring: 85% (disclosure event certain; favorable outcome probable)

Expected timeline: June-July 2026 (CCAR cycle)

Quality of evidence: Hard Data — The August 31, 2025 deadline is confirmed in Federal Reserve communications; JPM's $362.44B equity and 15.7% ROE provide quantitative foundation for favorable outcome

If it doesn't materialize: Continued disclosure lag would signal Fed contention over G-SIB surcharge, likely triggering 8-12% multiple compression as buyback uncertainty extends into 2027. JPM would face forced choice between EPS growth sacrifice and balance sheet shrinkage.

Catalyst 2: Investment Banking Recovery to 85-90% of 2021 Peak

Probability of occurring: 55% (market-dependent, not company-controlled)

Expected timeline: Q3-Q4 2026

Quality of evidence: Soft Signal — M&A pipeline data, Fed commentary on financial conditions, and JPM's market share position are observable but not deterministic; recovery requires macro cooperation

If it doesn't materialize: Fee income stagnation would force greater reliance on NII and trading, compressing ROE toward 13-14% and justifying 12x multiple. Stock would likely trade $250-265 range.

Catalyst 3: Treasury Clearing Mandate Delay Extension

Probability of occurring: 60% (regulatory discretion)

Expected timeline: Q2-Q3 2026

Quality of evidence: Soft Signal — SEC has confirmed delay through mid-2026; extension depends on industry readiness and political factors

If it doesn't materialize: Mandate implementation would compress JPM's estimated $2-3B annual rates market-making revenue advantage, forcing share loss to Citadel Securities and Virtu. Immediate 3-5% stock impact, with longer-term structural multiple compression.

Catalyst 4: Headquarters Synergy Realization

Probability of occurring: 70% (execution-dependent)

Expected timeline: 2026-2027

Quality of evidence: Thesis Only — $400-500M annual savings estimate based on real estate industry benchmarks and JPM's disclosed lease obligations; no quantified guidance from management

If it doesn't materialize: Technology migration disruption or delayed occupancy cost savings would undermine positive operating leverage narrative, particularly if NII compression accelerates. Risk of 'execution discount' 5-8% multiple compression.

Overall Value Trap Risk: MEDIUM

The SCB catalyst is hard-data supported with high probability, but the IB recovery and Treasury clearing catalysts are market/regulatory dependent with <60% probability. The headquarters synergy is thesis-only with execution risk. The trap scenario: SCB resolves favorably but IB fails to recover and NII compresses faster than expected, leaving JPM with capital return optionality but no earnings growth to distribute. This would validate the 14x multiple as fair but not cheap, trapping value investors in a 'dead money' stock through 2027.